Patent 10,471,072 Landscape for Estradiol Soft Gelatin Capsules for Dyspareunia: Scope, Claim Coverage, and US Competitive Freedom-to-Operate
US Patent 10,471,072 covers a narrow administration and formulation concept: a soft gelatin capsule delivers a liquid estradiol composition targeted to vaginal tissue for treating moderate-to-severe dyspareunia, with explicit drug load (4 to 25 µg estradiol), viscosity window (50 to 1000 cP at 25°C), and a specific in-capsule excipient class to increase viscosity. Independent claim 1 is a method-of-treatment claim that ties together (i) insertion depth (about two inches), (ii) capsule type (soft gelatin), (iii) daily-to-maintenance dosing schedule, (iv) viscosity and spread/absorption behavior, and (v) the estradiol dose range. Dependent claims narrow patient positioning, viscosity sub-range, viscosity excipient composition, specific estradiol strengths, and dosing regimen.
What does US Patent 10,471,072 claim for treating dyspareunia with estradiol soft gelatin capsules?
Direct answer: Claim 1 is a method for treating moderate to severe dyspareunia by inserting a soft gelatin capsule containing a liquid estradiol composition into the vagina to about two inches, where the liquid has viscosity 50–1000 cP at 25°C and contains 4–25 µg estradiol plus a viscosity-increasing excipient that enables spreading over vaginal tissue with vaginal absorption.
Independent claim 1: element-by-element scope
Claim 1 can be decomposed into claim-limiting requirements. A competitor’s product must meet all elements to infringe.
A. Indication and patient population
- Method for treating moderate to severe dyspareunia in a human subject.
B. Dosage form and route
- Insert a soft gelatin capsule containing a liquid pharmaceutical composition into the vagina.
C. Insertion depth limitation
- Insert about two inches into the vagina.
D. Estradiol potency range
- Composition comprises about 4 μg to about 25 μg of estradiol.
E. Viscosity and measurement conditions
- Composition viscosity is about 50 cP to about 1000 cP at 25° C.
- Viscosity is measured at 25°C and expressed in cP (centipoise).
F. Excipients and functional behavior
- Composition contains an excipient that increases viscosity.
- Functional language: the composition spreads over the vaginal tissue and estradiol is absorbed by the vaginal tissue.
G. Treatment mechanism phrased as outcome
- The method is framed around tissue spread and absorption, but infringement is driven by meeting structural/parameter elements (capsule, dose, viscosity, insertion depth). The “spreading/absorbed” language can be used to argue whether the formulation behaves as required, but the viscosity window is the measurable anchor.
Dependent claims 2–7: narrowing gates
Claim 2 (position during insertion)
- Reclined position while inserting the soft gelatin capsule.
Claim 3 (alternative position)
- Standing position while inserting the capsule.
Claim 4 (viscosity sub-range)
- Viscosity 50–380 cP at 25°C.
Claim 5 (excipient class)
- Viscosity-increasing excipient comprises:
- polyethylene glycol long chain saturated fatty acid esters, and/or
- ethylene glycol long chain saturated fatty acid esters,
- or mixtures.
Claim 6 (estradiol strength endpoints)
- Composition comprises 4 µg estradiol or 10 µg estradiol.
Claim 7 (dosage schedule)
- Insert once daily for two weeks, then twice weekly thereafter.
Practical infringement “must-haves”
To practice the claimed method in the US, a defendant must perform a method matching:
- moderate-to-severe dyspareunia treatment intent,
- soft gelatin capsule insertion with about two inches depth,
- liquid composition with 4–25 µg estradiol,
- viscosity 50–1000 cP at 25°C,
- viscosity-increasing excipient that includes the specified ester class if dependent claims are asserted,
- spread/absorption behavior, and
- dosing schedule if claim 7 is invoked.
How narrow are the viscosity and dosing ranges in US 10,471,072?
Direct answer: The core claim locks viscosity to 50–1000 cP at 25°C and estradiol to 4–25 µg. Dependent claim 4 tightens viscosity to 50–380 cP, and claim 6 narrows estradiol to 4 µg or 10 µg.
Viscosity window risk points for design-around
A competitor can reduce infringement risk by operating outside the viscosity ranges or outside the excipient class, but patent coverage will depend on literal infringement and equivalents arguments.
- Core viscosity range: 50 to 1000 cP at 25°C
- Narrow range: 50 to 380 cP at 25°C (claim 4)
Key parameter: “about” expands scope. Still, the range boundary is central. A formulation at 40 cP at 25°C is an immediate literal off-ramp; “about 50 cP” may still be argued, but the numeric range remains a strong anchor for claim construction.
Estradiol dosing risk points
- Core dose: about 4 to about 25 µg
- Narrow endpoints: 4 µg or 10 µg (claim 6)
If a competitor formulates outside the 4–25 µg window, it avoids claim 1’s literal dose limitation.
What excipient and formulation features does the patent require beyond estradiol and viscosity?
Direct answer: Claim 1 requires an excipient that increases viscosity enabling spreading and absorption. Dependent claim 5 specifically requires viscosity-increasing excipients to be polyethylene glycol long chain saturated fatty acid esters and/or ethylene glycol long chain saturated fatty acid esters.
Excipient chemistry: claim 5 is a targeted design lock
- Polyethylene glycol (PEG) long chain saturated fatty acid esters
- Ethylene glycol (EG) long chain saturated fatty acid esters
- Or mixtures
A formulation using different viscosity-builders (silicones, carbomers, cellulose derivatives, hyaluronic acid systems, synthetic polymers like PVP alone, or surfactant-thickened aqueous systems without the specified ester structure) is less likely to meet claim 5, but could still infringe claim 1 if it still meets viscosity and functional requirements and otherwise uses the required capsule and insertion depth.
How the “spreads over vaginal tissue” phrase matters
The “spreading” limitation can be used to argue whether viscosity and formulation behavior are consistent with the claim. Practically, the viscosity range suggests the intended rheology, but litigation would likely center on measurable viscosity and whether the formulation spreads under physiologic conditions.
What is the dosing and administration regimen covered by US 10,471,072?
Direct answer: Claim 7 fixes a regimen: once daily for two weeks, then twice weekly thereafter.
Administration regimen limitations
- Initial phase: daily dosing for 14 days
- Maintenance phase: twice per week after day 14
A competitor using a different titration, different maintenance frequency, or a different duration may avoid claim 7. However, claim 1 and claims 2–6 do not require the specific schedule unless claim 7 is asserted.
Patient positioning limitations
Claims 2 and 3 each provide a different insertion position:
- reclined position (claim 2)
- standing position (claim 3)
If a clinician uses a different posture (e.g., seated), those dependent claims may be harder to assert, but claim 1 still covers the method generally if other elements are met.
Insertion depth limitation: “about two inches”
This is unusually concrete. A design-around can focus on insertion depth practice and device geometry. Still, in litigation, “about two inches” can capture a clinical range. Competitors should assume evidentiary reliance on insertion practice, capsule size, applicator absence/presence, and insertion method.
How many claims are likely to be asserted: independent method vs dependent narrowing?
Direct answer: Litigation typically anchors to claim 1, then adds dependent claims where a product matches their additional constraints.
Litigation selection logic
- If a competitor’s formulation matches core estradiol dose and viscosity and uses a soft gelatin capsule with the required insertion depth, claim 1 is the likely starting point.
- If the competitor also uses PEG/EG long chain saturated fatty acid ester viscosity excipients, claim 5 becomes a strong add-on.
- If dosing schedule matches, claim 7 adds schedule-specific exposure.
- If the clinical instructions emphasize reclined or standing insertion, claims 2 or 3 can be appended depending on labeling and practice.
What design-around options exist against 10,471,072’s claim elements?
Direct answer: The most direct off-ramps are to exit the estradiol dose range, exit the viscosity range at 25°C, switch away from the specified ester excipient class (for claim 5), change capsule type (not soft gelatin), or change insertion depth practice and dosing regimen.
High-impact design-around levers
- Capsule type: use a non-soft-gelatin capsule or different delivery form
- Insertion depth: avoid administration consistent with “about two inches”
- Estradiol loading: formulate outside ~4–25 µg
- Viscosity: formulate outside ~50–1000 cP at 25°C
- Viscosity excipient chemistry: avoid PEG/EG long chain saturated fatty acid ester thickening (claim 5 target)
- Dosing schedule: alter from daily x 2 weeks then twice weekly (claim 7 target)
- Patient posture: may avoid dependent claims 2 or 3 but not claim 1
What does the patent likely cover in practice: product profile and commercialization risk?
Direct answer: The claim language maps to an intravaginal estradiol liquid fill encapsulated in a soft gelatin capsule designed for limited insertion depth and a specific viscosity-controlled spread.
Product profile signals implied by the claim
- Estradiol microdose: 4–25 µg
- Soft gelatin capsule: suggests a sealed liquid or semiliquid fill rather than an insert tablet/pessary
- Viscosity targeted for tissue spread: thick enough to localize, not so viscous as to prevent spreading
- Dosing cadence: initial daily induction then twice-weekly maintenance mirrors clinical titration approaches in vaginal estrogen regimens
How strong is the patent estate for method scope if asserted against other estradiol vaginal products?
Direct answer: Strength depends on how many existing or pipeline products match all claim elements, especially the combined constraints of soft gelatin capsule + insertion depth + viscosity at 25°C + estradiol microdose + tissue spread/absorption framing.
Scenario-based exposure mechanics
- Highest exposure: if a competitor has an estradiol microdose soft gel capsule with similar viscosity and similar insertion depth practices and uses PEG/EG long chain ester excipients.
- Moderate exposure: if the competitor matches the dose and viscosity but differs in excipient class or capsule material/type.
- Lower exposure: if dose or viscosity are outside the ranges, or if delivery is not a soft gelatin capsule, or insertion depth/dosing regimen differs.
Because claim 1 is a method claim, enforcement generally requires evidence of the method being used on the labeled patient population.
What is the US patent landscape around US 10,471,072 for similar dyspareunia or vaginal estradiol approaches?
Direct answer: The provided prompt includes only claim text and not the patent’s bibliographic record, priority filings, CPC classes, or any related US continuations/divisionals. Without those, an accurate landscape cannot be constructed.
The same applies to:
- Orange Book listings for specific NDC products
- other US patents held by the same assignee covering formulation, method of treatment, capsule design, or excipients
- litigation and Paragraph IV challenges tied to specific ANDAs
- regulatory pathway status for any particular estradiol vaginal product
No complete, accurate landscape can be produced from the claim excerpt alone.
Key Takeaways
- US 10,471,072 claim 1 is a tight method bundle: moderate-to-severe dyspareunia treatment using a soft gelatin capsule inserted about two inches, containing a liquid estradiol composition with 4–25 µg estradiol and 50–1000 cP viscosity at 25°C.
- Dependent claims create additional fences: 50–380 cP (claim 4), PEG/EG long chain saturated fatty acid ester excipients (claim 5), 4 µg or 10 µg estradiol (claim 6), reclined/standing insertion (claims 2–3), and a specific regimen of daily for 2 weeks then twice weekly (claim 7).
- Design-around focus should prioritize leaving one of the central numeric gates (estradiol dose or viscosity), changing the delivery/capsule form factor (not soft gelatin), changing insertion depth and/or regimen, and avoiding the specified ester excipient class when trying to defeat claim 5.
FAQs
- What evidence would be used to prove the viscosity range at 25°C for infringement of a 50–1000 cP claim?
- How do “about” terms typically affect numeric limitations like 4–25 µg estradiol and 50–1000 cP viscosity in method claims?
- If a product’s excipient thickener is outside PEG/EG long chain saturated fatty acid esters, can it still infringe claim 1?
- Does the reclined vs standing limitation (claims 2–3) matter if a clinician uses a different posture?
- If dosing schedule differs from “once daily for two weeks, then twice weekly,” is exposure limited to claim 1 rather than claim 7?
References (APA)
- Provided claim text for US Patent 10,471,072 (user-supplied).
